Department of Oncology, Mudanjiang Cancer Hospital, Mudanjiang, China.
Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):691-698. doi: 10.26355/eurrev_202001_20046.
This study aims to illustrate the potential role of MAGI1-IT1 in the progression of non-small cell lung cancer (NSCLC) and the underlying mechanism.
The relative level of MAGI1-IT1 in normal lung tissues and NSCLC tissues was determined. Its level in NSCLC patients with different tumor sizes (<5 cm or >5 cm), metastatic statues (positive or negative), and tumor staging (stage I+II or stage III+IV) was detected as well. The prognostic potential of MAGI1-IT1 in evaluating the overall survival (OS) and progression-free survival (PFS) of NSCLC patients was assessed by the Kaplan-Meier method. In A549 and PC-9 cells, the regulatory effect of MAGI1-IT1 on the proliferative ability was examined by the cell counting kit-8 (CCK-8), colony formation, and 5-Ethynyl-2'-deoxyuridine (EdU) assay. The target miRNA of MAGI1-IT1 and the target gene binding to miRNA-512-3p were predicted using the Diana database. The interactions among MAGI1-IT1/miRNA-512-3p/AKT1 regulatory loop were tested by the Dual-luciferase reporter gene assay and RNA immunoprecipitation (RIP) assay. At last, the rescue experiments were carried out to uncover the regulatory effect of MAGI1-IT1/AKT1 axis on NSCLC progression.
MAGI1-IT1 was upregulated in NSCLC tissues. Its level was higher in NSCLC patients with larger tumor size, positive metastasis, or advanced stage. High level of MAGI1-IT1 predicted worse OS and PFS in NSCLC patients. The knockdown of MAGI1-IT1 remarkably attenuated the proliferative ability in A549 and PC-9 cells. MAGI1-IT1 could target miRNA-512-3p, and AKT1 was the target gene of miR-512-3p. The overexpression of AKT1 stimulated lung cancer cells to proliferate. Of note, the elevated proliferative rate in lung cancer cells overexpressing AKT1 was reversed by the silence of MAGI1-IT1.
MAGI1-IT1 is upregulated in NSCLC tissues and cell lines, and predicts a poor prognosis in NSCLC patients. MAGI1-IT1 stimulates proliferative ability in NSCLC by upregulating the AKT1 level by binding to miRNA-512-3p.
本研究旨在阐明 MAGI1-IT1 在非小细胞肺癌(NSCLC)进展中的潜在作用及其机制。
检测正常肺组织和 NSCLC 组织中 MAGI1-IT1 的相对水平。检测不同肿瘤大小(<5cm 或>5cm)、转移状态(阳性或阴性)和肿瘤分期(I+II 期或 III+IV 期)的 NSCLC 患者中 MAGI1-IT1 的水平。采用 Kaplan-Meier 法评估 MAGI1-IT1 对 NSCLC 患者总生存期(OS)和无进展生存期(PFS)的预后预测价值。在 A549 和 PC-9 细胞中,通过细胞计数试剂盒-8(CCK-8)、集落形成和 5-乙炔基-2'-脱氧尿苷(EdU)检测评估 MAGI1-IT1 对增殖能力的调控作用。利用 Diana 数据库预测 MAGI1-IT1 的靶 miRNA 及与 miRNA-512-3p 结合的靶基因。通过双荧光素酶报告基因检测和 RNA 免疫沉淀(RIP)检测验证 MAGI1-IT1/miRNA-512-3p/AKT1 调控环的相互作用。最后,进行挽救实验以揭示 MAGI1-IT1/AKT1 轴对 NSCLC 进展的调控作用。
MAGI1-IT1 在 NSCLC 组织中上调。肿瘤体积较大、转移阳性或分期较晚的 NSCLC 患者中 MAGI1-IT1 水平较高。MAGI1-IT1 水平高预示 NSCLC 患者 OS 和 PFS 较差。MAGI1-IT1 敲低显著抑制 A549 和 PC-9 细胞的增殖能力。MAGI1-IT1 可靶向 miRNA-512-3p,AKT1 是 miR-512-3p 的靶基因。过表达 AKT1 可刺激肺癌细胞增殖。值得注意的是,过表达 AKT1 的肺癌细胞增殖率的升高可被 MAGI1-IT1 的沉默所逆转。
MAGI1-IT1 在 NSCLC 组织和细胞系中上调,并预示 NSCLC 患者预后不良。MAGI1-IT1 通过与 miRNA-512-3p 结合上调 AKT1 水平,刺激 NSCLC 细胞的增殖能力。